CURRICULUM VITAE

FORMATO EUROPEO PER IL CURRICULUM VITAE

INFORMAZIONI PERSONALI

Nome e Cognome	Michele D'Ambrosio
Data di nascita	[redacted]
Telefono	[redacted]
Telefono cellulare	[redacted]
Indirizzo posta elettronica	[redacted]
Incarico attuale	PhD Candidate – Sapienza University of Rome

ISTRUZIONE E FORMAZIONE

• Date (da – a)	2014-2021
• Nome e tipo di istituto di istruzione o formazione	Sapienza University of Rome. Master's Degree in Pharmaceutical Chemistry and Technology
• Qualifica conseguita	Master's Degree
• Date (da – a)	Febrauary – June 2018
• Nome e tipo di istituto di istruzione o formazione	Visiting Erasmus+ Student, University of Surrey, Guildford, England
• Date (da – a)	November 2021 – October 2024
• Nome e tipo di istituto di istruzione o formazione	Sapienza University of Rome, Department of Chemistry and Technology of Drugs. Doctoral course in Pharmaceutical Sciences, XXXVII Cycle
• Date (da – a)	September 2023 – May 2024
• Nome e tipo di istituto di istruzione o formazione	Visiting Scholar, University of Pennsylvania, Philadelphia, USA

MADRELINGUA

ITALIAN

ALTRE LINGUE

ENGLISH

• Capacità di lettura EXCELLENT
• Capacità di scrittura EXCELLENT
• Capacità di espressione orale EXCELLENT

CAPACITÀ E COMPETENZE TECNICHE

Con computer, attrezzature specifiche, macchinari, ecc.

As a researcher in the field of pharmaceutical sciences, my work is focused on drug design and the discovery of novel anticancer agents.
One area of my research is focused on the development of tubulin polymerization inhibitors. These compounds have shown promising anticancer activity in preclinical studies and are being investigated as potential therapeutics. Amongst these, ferroptosis inducers stand out as a distinct class, representing a promising strategy for the treatment of cancer. My work has involved the design and synthesis of tubulin polymerization inhibitors that can induce ferroptosis in cancer cells, and the characterization of these compounds using various analytical techniques.
Another area of my research is focused on the development of allosteric modulators of the Wnt/β-Catenin pathway, a new challenging target for cancer therapy, due to its double-sided aspect. The aim is to design and synthesize new modulators in order to downregulate the aberrant activity of the pathway, while preserving its basal activity in healthy tissues.
During my tenure as a visiting scholar at the University of Pennsylvania, my primary research centered on natural products. Specifically, I dedicated my efforts to the total synthesis of Discodermolide and its analogues, compounds exhibiting significant potential in combating cancer through their promising biological activity.
Overall, my experience in drug design, drug discovery, medicinal chemistry, and the analysis of compounds using techniques such as NMR provides me with a strong foundation for a career in pharmaceutical research.

ALTRO (PARTECIPAZIONE A CONVEGNI, SEMINARI, PUBBLICAZIONI, COLLABORAZIONI A RIVISTE, ECC. ED OGNI ALTRA INFORMAZIONE CHE IL COMPILANTE RITIENE DI DOVER PUBBLICARE)

Articles

1. Puxeddu, M.; Wu, J.; Bai, R.; D'Ambrosio, M.; Nalli, M.; Coluccia, A.; Manetto, S.; Ciogli, A.; Masci, D.; Urbani, A.; Fionda, C.; Coni, S.; Bordone, R.; Canettieri, G.; Bigogno, C.; Dondio, G.; Hamel, E.; Liu, T.; Silvestri, R.; La Regina, G. Induction of Ferroptosis in Glioblastoma and Ovarian Cancers by a New Pyrrole Tubulin Assembly Inhibitor. *Journal of Medicinal Chemistry* **2022**, *65* (23), 15805–15818.
2. Nalli, M.; Di Magno, L.; Wen, Y.; Liu, X.; D'Ambrosio, M.; Puxeddu, M.; Parisi, A.; Sebastiani, J.; Sorato, A.; Coluccia, A.; Ripa, S.; Di Pastena, F.; Capelli, D.; Montanari, R.; Masci, D.; Urbani, A.; Naro, C.; Sette, C.; Orlando, V.; D'Angelo, S.; Biagioni, S.; Bigogno, C.; Dondio, G.; Pastore, A.; Stornaiuolo, M.; Canettieri, G.; Liu, T.; Silvestri, R.; La Regina, G. Novel N-(Heterocyclylphenyl)Benzensulfonamide Sharing an Unreported Binding Site with T-Cell Factor 4 at the β-Catenin Armadillo Repeats Domain as an Anticancer Agent. *ACS Pharmacology & Translational Science* **2023**, *6* (7), 1087–1103.
3. Masci, D.; Puxeddu, M.; Di Magno, L.; D'Ambrosio, M.; Parisi, A.; Nalli, M.; Bai, R.; Coluccia, A.; Sciò, P.; Orlando, V.; D'Angelo, S.; Biagioni, S.; Urbani, A.; Hamel, E.; Nocentini, A.; Filiberti, S.; Turati, M.; Ronca, R.; Kopecka, J.; Riganti, C.; Fionda, C.; Bordone, R.; Della Rocca, G.; Canettieri, G.; Supuran, C. T.; Silvestri, R.; La Regina, G. 4-

(3-Phenyl-4-(3,4,5-Trimethoxybenzoyl)-1H-Pyrrol-1-Yl)Benzenesulfonamide, a Novel Carbonic Anhydrase and Wnt/β-Catenin Signaling Pathway Dual-Targeting Inhibitor with Potent Activity against Multidrug Resistant Cancer Cells. *Journal of Medicinal Chemistry* **2023**, *66* (21), 14824–14842.

4. Puxeddu, M.; Ling, L.; Ripa, S.; D'Ambrosio, M.; Nalli, M.; Parisi, A.; Sciò, P.; Coluccia, A.; Granese, A.; Santelli, M.; Masci, D.; Cuřínová, P.; Naro, C.; Sette, C.; Pastore, A.; Stornaiuolo, M.; Bigogno, C.; Dondio, G.; Di Magno, L.; Canettieri, G.; Liu, T.; Silvestri, R.; La Regina, G. Development of N-(4-(1H-Imidazol-1-yl)phenyl)-4-chlorobenzenesulfonamide, a Novel Potent Inhibitor of β-Catenin with Enhanced Antitumor Activity and Metabolic Stability. *Journal of Medicinal Chemistry* **2024**.

Poster communications

M. D'Ambrosio. Discovery of a novel pyrrole derivative as a tubulin polymerization inhibitor agent capable of inducing ferroptosis in glioblastoma and ovarian cancers. European School of Medicinal Chemistry 2022, July 3rd – 7th, **2022**, Urbino, Italy.

Oral communications

M. D'Ambrosio. New tubulin polymerization inhibitors as ferroptosis inducers to treat cancer. XI EDITION BeMM Symposium, September 30th, **2024**, Rome, Italy.